S&P DJ Indices Announces March Quarterly Review
Filed with ASX · · 9 pages · English
Story so far
Earlier from Immutep
- S&P DJ Indices Announces March Quarterly Rebalance
- Appendix 4E & 2016 Full Year Statutory Accounts
- European Patent Grants for IMP731 Antibody
- PRR Collaborates In New Clinical Trial For Imp321
- First Data From Phase IIb Clinical Trial of Imp321
Later from Immutep
- Wuxi & Prima sign MOU for strategic partnership
- Prima receives UK approval for AIPAC study
- Prima announces AIPAC clinical trial data
- Prima announces TACTI-mel clinical trial data
- Prima announces new LAG-3 agonist antibody product candidate
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep